Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Azathioprine
Drug ID BADD_D00195
Description Azathioprine is a prodrug of 6-mercaptopurine, first synthesized in 1956 by Gertrude Elion, William Lange, and George Hitchings in an attempt to produce a derivative of 6-mercaptopurine with a better therapeutic index.[A189678,A189687,A189690] Azathioprine is used to treat inflammatory conditions like rheumatoid arthritis and as an immunosuppressant in the prevention of renal transplant rejection.[L11214] Azathiprine was granted FDA approval on 20 March 1968.[L11214]
Indications and Usage Azathioprine is indicated to treat rheumatoid arthritis and prevent renal transplant rejection.[L11214]
Marketing Status approved
ATC Code L04AX01
DrugBank ID DB00993
KEGG ID D00238
MeSH ID D001379
PubChem ID 2265
TTD Drug ID D07QCE
NDC Product Code 62991-2189; 65649-231; 67877-492; 68084-229; 68382-120; 51407-182; 68382-118; 72789-129; 46014-1110; 70771-1141; 60219-1076; 60219-2036; 60219-2037; 68382-003; 48954-909; 51927-0071; 68682-241; 70518-3544; 70771-1140; 51927-2258; 54766-590; 65841-602; 12780-0300; 38779-0312; 66122-0009; 42291-063; 68462-502; 71610-124; 42291-071; 68682-231; 70771-1139; 15308-0732; 49452-0783; 67877-493; 51552-0779; 65649-241; 67877-494; 67877-495; 68382-119; 42973-143
UNII MRK240IY2L
Synonyms Azathioprine | Azothioprine | Imurel | Imuran | Immuran | Azathioprine Sodium | Sodium, Azathioprine | Azathioprine Sodium Salt | Azathioprine Sulfate
Chemical Information
Molecular Formula C9H7N7O2S
CAS Registry Number 446-86-6
SMILES CN1C=NC(=C1SC2=NC=NC3=C2NC=N3)[N+](=O)[O-]
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hypersensitivity vasculitis01.01.04.008; 10.02.02.017; 23.06.02.005; 24.12.04.0130.000627%-
Hypertension24.08.02.001--
Hyperthermia08.05.01.001; 12.05.01.002---
Hyperventilation19.01.02.004; 22.02.01.006---
Hypoalbuminaemia09.01.02.003; 14.10.01.0020.000940%
Hypocalcaemia14.04.01.0040.000627%
Hypogammaglobulinaemia10.03.02.0070.000470%-
Hypokalaemia14.05.03.002--
Hypokinesia17.01.02.009---
Hypopnoea22.02.01.021---
Hypoproteinaemia09.01.02.004; 14.10.01.0030.000313%-
Hypotension24.06.03.002--
Hypotonia15.05.04.008; 17.05.02.002---
Hypoxia22.02.02.0030.000940%
IIIrd nerve paralysis06.05.02.011; 17.04.02.0030.000470%-
Ileal perforation07.04.06.0100.000470%
Ileal ulcer07.04.06.0080.001097%
Ileus07.13.01.0010.001097%
Immune system disorder10.02.01.0010.000313%-
Impaired healing08.03.02.0010.000940%-
Incontinence07.01.06.011; 17.05.01.006; 20.02.02.004---
Increased tendency to bruise01.01.03.005; 23.06.01.009; 24.07.06.012---
Infection11.01.08.002---
Inflammatory bowel disease07.08.01.0160.001253%-
Influenza like illness08.01.03.0100.002256%
Inguinal hernia07.16.02.0010.000313%-
Injection site bruising08.02.03.042; 12.07.03.042; 23.03.11.015; 24.07.06.0170.000689%-
Injection site erythema08.02.03.001; 12.07.03.001; 23.03.06.0150.003603%-
Injection site extravasation08.02.03.002; 12.07.03.0020.000689%-
Injection site haemorrhage08.02.03.005; 12.07.03.005; 24.07.01.0100.000846%-
The 8th Page    First    Pre   8 9 10 11 12    Next   Last    Total 25 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene